The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells.

Provided herein are, in various embodiments, methods of detecting an acute inflammatory response associated with a viral infection in a patient, methods of predicting a likelihood of developing an acute inflammatory response (e.g., an acute respiratory distress syndrome) in a patient having a viral infection, such as a SARS-CoV2 infection, and methods of preparing a bodily fluid sample that is useful for performing the disclosed methods. The present invention also provides methods of treating a patient having a viral infection with a therapy that inhibits acute inflammation, such as acute inflammation mediated by the kinin-kallikrein system and/or the renin-angiotensin system (RAS).

Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

Renin-based assays and kits for quantitative measurement of hepcidin, preferably biologically active hepcidin-25. Also provided are treatment modalities for the management of blood pressure and methods of determining or monitoring a subject's hepcidin status, status of a hepcidin-related disorder, and/or response to treatment by employing the hepcidin assay or kit provides novel treatment modalities for the management of blood pressure.

Provided herein are methods, systems and kits for use in identifying a subject with an increased risk of developing severe forms of inflammatory bowel disease (IBD), based at least in part, on an expression of one or more biomarkers detected in a biological sample obtained from the subject. Also provided are methods, systems and kits for treating, or optimizing the treatment for, the IBD based, at least in part, on the expression the one or more biomarkers. In some embodiments, the one or more biomarkers is angiotensin-converting enzyme 2 (ACE2), the host receptor for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2).

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.